

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number
WO 2005/035779 A2

(51) International Patent Classification⁷: C12Q

(21) International Application Number: PCT/US2004/033391

(22) International Filing Date: 12 October 2004 (12.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/510,086	10 October 2003 (10.10.2003)	US
60/526,571	4 December 2003 (04.12.2003)	US
60/567,771	5 May 2004 (05.05.2004)	US

(71) Applicant (for all designated States except US): POWERJECT VACCINES, INC [US/US]; 585 Science Drive, Madison, WI 53711 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRAUN, Ralph,

Patrick [US/US]; 8551 Research Way Blvd., Middleton, WI 53562 (US). DONG, Lichun [US/US]; 8551 Research Way Blvd., Middleton, US 53562 (US).

(74) Agent: PEET, Richard, C.; FOLEY & LARDNER, 3000 K Street, N.W., Suite 500, Washington, DC 20007-5143 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,


[Continued on next page]

(54) Title: METHOD

(ICP27 plasmid)



(PJV7630)



(57) Abstract: The invention relates to a method of eliciting a T cell response against a T cell epitope in a host mammalian subject, which method comprises: (i) a first immunisation that comprises at least two administrations which are from 1 to 14 days apart to the subject, wherein each administration comprises administering a nucleotide of interest (NOI) encoding the T cell epitope, and optionally (ii) a second immunisation that comprises at least one administration to the subject of (a) a NOI encoding the T cell epitope, or (b) a protein comprising the T cell epitope, wherein the time between the first administration of the first immunisation, and the first administration of the second immunisation, is from 21 to 365 days.

BEST AVAILABLE COPY

WO 2005/035779 A2



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.